Revelation Biosciences Secures FDA Agreement for Gemini AKI Approval Pathway
REVB sits 18% above its 52-week low of $0.707 on elevated volume (28× avg).
Summary
Revelation Biosciences announced a definitive agreement with the FDA on a single adaptive Phase 2/3 study and composite endpoint for Gemini's approval pathway in Acute Kidney Injury (AKI), significantly de-risking its lead program.
Key Events · Product Development and Regulatory · REVB
-
FDA Agreement for AKI Pathway
Revelation Biosciences reached an agreement with the FDA on a clear approval pathway for Gemini as a treatment for Acute Kidney Injury (AKI).
-
Single Pivotal Study Design
The agreement includes a single adaptive Phase 2/3 clinical study, which will evaluate different dosing regimens in Part 1 (Phase 2) and then proceed to a Phase 3 study using the safest regimen.
-
Defined Composite Endpoint
The FDA agreed on a clinically relevant composite endpoint comprising death and/or the need for dialysis, which will be sufficient for a New Drug Application (NDA) submission.
-
Significant Market Opportunity
AKI represents a substantial unmet medical need, with the company highlighting a potential $5 billion market, indicating a significant opportunity for Gemini.
Analysis · REVB · Life Sciences
Revelation Biosciences has achieved a significant regulatory milestone by reaching an agreement with the FDA on a clear approval pathway for its lead drug candidate, Gemini, for Acute Kidney Injury (AKI). This agreement specifies a single adaptive Phase 2/3 clinical study design and a clinically relevant composite endpoint (death and/or need for dialysis), substantially de-risking the development process. For a clinical-stage company with a small market capitalization, this clarity from the FDA provides a strong positive signal regarding the potential for Gemini to address a large unmet medical need with a multi-billion dollar market opportunity. The company plans to initiate the pivotal study in 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REVB was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.71 to $20.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.